BMS/AZ - Onglyza: ok to add on

The CHMP has adopted a positive opinion on Bristol-Myers Squibb/ AstraZeneca's DPP 4 inhibitor Onglyza (saxagliptin) for type 2 diabetes as an add-on combination therapy to metformin, a thiazolidinedione, or a sulphonylurea.